Clinical Trial Update: Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, pharmacokinetics, and renal potassium clearance in chronic kidney disease; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Eli Lilly and Company

Snippet

Sponsor: Eli Lilly and Company | Conditions: Chronic Kidney Disease | Phase 1 | Status: COMPLETED | Results posted: 2019-06-03